Oregon to Hold First-Ever Hearing on Adding Female Orgasmic Disorder to Medical Marijuana Program

Oregon will hold a three-day hearing from February 3 to February 5 to determine whether Female Orgasmic Disorder should be recognized as a qualifying condition under the Oregon Medical Marijuana Program, marking the first major appeal of its kind anywhere in the country. The hearing will be conducted before the Office of Administrative Hearings and stems from an appeal filed on behalf of petitioner Rebecca Andersson, whose request to add the condition was previously denied by the Oregon Health Authority. A legal memorandum submitted January 16 argues that the existing scientific record already meets Oregon’s legal threshold, which requires only that marijuana may mitigate symptoms and that its benefits outweigh potential risks. The filing contends the state improperly applied a higher evidentiary standard than required under administrative rules.

Supporters say the case represents a pivotal moment for both women’s health policy and medical marijuana law. Suzanne Mulvehill, a clinical sexologist and executive director of the Female Orgasm Research Institute and Women’s Cannabis Project, said the proceeding is the first to fully examine the issue through a formal legal process that allows expert testimony, scientific interpretation, and cross-examination of evidence.

Illinois and Connecticut have already approved Female Orgasmic Disorder as a qualifying condition for medical marijuana, while New Mexico has advanced a similar petition through board-level approval and is awaiting final review. Other states have reached different conclusions, highlighting what advocates describe as inconsistent standards across the country. Backers of the Oregon appeal argue the case could establish a clearer framework for how sexual health conditions are evaluated nationwide.

The hearing will feature testimony from 12 nationally and internationally recognized experts in fields including cannabinoid medicine, gynecology, psychiatry, neuroscience, sexual medicine, trauma, and women’s health. Collectively, the witnesses bring decades of clinical experience and hundreds of peer-reviewed publications. Testimony is expected to focus on biological plausibility, clinical outcomes, and patient-reported improvements tied to cannabis use.

Female Orgasmic Disorder affects up to 41% of women and currently has no FDA-approved pharmacological treatments. Research has linked orgasmic difficulty to trauma, anxiety, depression, chronic stress, and nervous system dysregulation. Multiple peer-reviewed studies cited by advocates report improvements in orgasmic function, reduced sexual distress, and enhanced bodily awareness among women using cannabis.

At the core of the appeal are three arguments: that the evidentiary record already satisfies Oregon’s mitigation standard, that no evidence shows risks outweigh benefits, and that the original denial relied on an improperly high scientific bar, including a demand for randomized controlled trials not required by state rules.

If successful, the Oregon case could become a defining precedent, influencing how medical marijuana programs across the U.S. approach women’s sexual health conditions moving forward.